vimarsana.com
Home
Live Updates
Momna ali
Live Breaking News & Updates on Momna ali
Proposed Golimumab Biosimilar AVT05 Meets Primary Endpoints in Moderate to Severe RA
At the end of the trial, the study met its primary outcome, indicating therapeutic equivalence between the biosimilar (AVT05) and reference golimumab.
Robert-wessman
,
Momna-ali
,
Cameroni-alvotech
,
Rheumatology-informatics-system
,
Clinical-disease-activity-index
,
Disease-activity
,
Rheumatoid-arthritis
,
Globenewswire-news
,
Alvotech's AVT05 emerges as leading contender in rheumatoid arthritis market
The patent for Janssen’s second-generation, tumour necrosis factor-alpha (TNF)-a inhibitor Simponi (golimumab), is scheduled to expire in 2024 and in 2025 in the US and EU, respectively.
Japan
,
Australia
,
Advanz-pharma
,
Momna-ali
,
Rheumatoid-arthritis
,
Global-drug-forecast
,
Market-analysis
,
Bio-developments
,
Arkets-amp-regulations
,
Merging-markets
,
Heumatoid-arthritis